Huaren Health released its 2026 interim report. First-half net profit attributable to the parent was 136 million yuan, up 31.0% year on year. Operating revenue was 2.82 billion yuan, up 12.8% year on year. Net profit attributable to the parent after deducting non-recurring items was 132 million yuan, up 31.0% year on year. Net operating cash flow was 410 million yuan, down 23.0% year on year. Earnings per share were 0.3398 yuan. In the second quarter, operating revenue was 1.40 billion yuan, up 13.5% year on year, and net profit attributable to the parent was 56.57 million yuan, up 33.0% year on year. As of the end of the second quarter, the company's total assets were 5.468 billion yuan, down 0.4% from the end of the previous year, and net assets attributable to the parent were 2.119 billion yuan, up 1.1% from the end of the previous year. The company said its main operating businesses did not experience major changes during the reporting period. Pharmaceutical retail, pharmaceutical marketing, and drug research and development and production continued to advance steadily, and overall operations maintained steady growth.
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl AFirst-half net profit up 31.0% year on year, with revenue up 12.8%.
